Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

首页> 外文期刊>The lancet. Respiratory medicine. >Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

【24h】

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

机译：Nintedanib患者患有初步抗体性肺病疾病 - 亚组通过内联肺病诊断分析：随机，双盲，安慰剂，并联群试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We aimed to establish the effects of nintedanib in subgroups based on ILD diagnosis.

机译：背景技术联邦试验研究了尼林尼布与安慰剂在患有特发性肺纤维化（IPF）之外的患者患者中尼丁胺的疗效和安全性。我们的旨在基于ILD诊断建立尼宁尼在亚组中的影响。

著录项

来源
《The lancet. Respiratory medicine.》 |2020年第5期|共8页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类呼吸系及胸部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial [J] . The lancet. Respiratory medicine. . 2020,第5期

机译：Nintedanib患者患有初步抗体性肺病疾病 - 亚组通过内联肺病诊断分析：随机，双盲，安慰剂，并联群试验
2. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial [J] . Maher Toby M., Corte Tamera J., Fischer Aryeh, The lancet. Respiratory medicine. . 2020,第2期

机译：Pirfenidone患者患者无分类渐进式间质性肺病：双盲，随机，安慰剂控制，第2期试验
3. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS (TM)) [J] . Distler O., Brown K. K., Distler J. H. W., Clinical and experimental rheumatology . 2017,第4Suppla106期

机译：尼丁尼患者随机，安慰剂对照临床试验患者患有全身硬化相关间质肺病（Senscis（TM））
4. Longitudinal Alignment of Disease Progression in Fibrosing Interstitial Lung Disease [C] . Wolf-Dieter Vogl, Helmut Prosch, Christina Mueller-Mang, International conference on medical imaging computing and computer-assisted intervention . 2014

机译：纤维化间质性肺疾病疾病进展的纵向比对
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Design of the PF-ILD trial: a double-blind randomised placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease [O] . Kevin R Flaherty, Kevin K Brown, Athol U Wells, 2017

机译：PF-ILD试验的设计：Nintedanib在进行性纤维化间质性肺疾病患者中的双盲随机安慰剂对照的III期临床试验
7. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial [O] . Athol U Wells, Kevin R Flaherty, Kevin K Brown, 2020

机译：Nintedanib患者患有初步抗体性肺病疾病 - 亚组通过内联肺病诊断分析：随机，双盲，安慰剂控制，并联群试验

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

摘要

著录项

相似文献

相关主题

期刊订阅